Faron Lifted By US Immunotherapy Trial Approval
Plans For Breakthrough Status Application
Executive Summary
After a major setback to its lead asset last year, Faron looks to novel immunotherapy
You may also be interested in...
Finance Watch: Atlas Raises $450m Venture Fund For Biotech Breakthroughs
Both Atlas and Foresite Capital announced new funds focused on start-ups. Also, Flagship launched Vesalius with $75m in initial funding, Innoviva sold $225m in notes, Hookipa priced a $75m follow-on offering and job cuts were revealed by Epizyme, Flexion, Deciphera and Gemini.
Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?
Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.
Faron’s Traumakine Flops In Phase III
Faron Pharmaceuticals’ stock has plummeted more than 80% on the news its lead drug failed in a Phase III trial – the company will now shift its focus to an investigational cancer therapy, but this is yet to enter the clinic.